Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study

Table 1 Characteristics of 42 critically ill patients receiving vancomycin therapy, stratified for intermittent dosing or continuous infusion

Characteristic	All patients (n = 42)	Intermittent dosing (n = 18)	Continuous infusion (n = 24)	P ^*
Age (years)	58 [45 - 66]	58 [32 - 79]	58 [45 - 66]	0.755
Male sex	27 (64.3)	13 (72.2)	14 (58.3)	0.353
Weight (kg)	70 [61 - 85]	75 [65 - 88]	70 [61 - 85]	0.350
APACHE II score	16 [13 - 25]	17 [14 - 27]	16 [13 - 25]	0.920
SOFA score	6 [3 - 9]	5 [3 - 6]	6 [3 - 9]	0.595
Serum creatinine concentration (μmol/L)	65 [51 - 113]	64 [52 - 91]	74 [44 - 129]	0.751
Urinary creatinine clearance (mL/min.)	85 [60 - 106]	72 [20 - 90]	101 [74 - 167]	0.198
Renal replacement therapy	9 (21.4)	1 (5.6)	8 (33.3)	NA
Intermittent hemodialysis	2 (4.8)	0	2
Continuous renal replacement therapy	7 (16.7)	1	6

Data are described as median [1^st - 3^rd quartile] or n (%). ^*Indicates difference between intermittent dosing and continuous infusion of vancomycin. APACHE II, acute physiology and chronic health evaluation II; SOFA, sequential organ failure assessment; NA, not applicable as the expected count in at least one cell is less than 5.

ISSN: 1364-8535